Rechallenge therapy shows promise for Tough-to-Treat colorectal cancer
Disease control
Not yet recruiting
This phase 2 trial compares a rechallenge treatment (irinotecan plus cetuximab) against the current standard (trifluridine/tipiracil plus bevacizumab) for people with metastatic colorectal cancer whose disease has worsened after earlier therapies. Only patients with specific gene…
Phase: PHASE2 • Sponsor: Gruppo Oncologico Italia Meridionale • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC